

# miR-760 mediates hypoxia-induced proliferation and apoptosis of human pulmonary artery smooth muscle cells via targeting TLR4

YU-ZHONG YANG<sup>1\*</sup>, YUN-FENG ZHANG<sup>2\*</sup>, LEI YANG<sup>3</sup>, JING XU<sup>2</sup>, XU-MING MO<sup>1</sup> and WEI PENG<sup>1</sup>

Departments of <sup>1</sup>Cardiothoracic Surgery, <sup>2</sup>Pharmacy and <sup>3</sup>Digestion, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China

Received March 6, 2018; Accepted August 16, 2018

DOI: 10.3892/ijmm.2018.3862

**Abstract.** MicroRNAs (miRNAs) have a key role in the pathogenesis of pulmonary arterial hypertension (PAH), a disease characterized by enhanced proliferation and reduced apoptosis of pulmonary artery smooth muscle cells. In the present study, miR-760 was demonstrated to be downregulated in PAH lung tissues compared with normal lung tissues, an effect that may be associated with the development of PAH. Hypoxia is an important stimulus for human pulmonary artery smooth muscle cell (hPASC) proliferation and the occurrence of PAH. Therefore, the effect of miR-760 in hypoxia-treated and normal hPASCs was investigated. Expression of exogenous miR-760 decreased cell proliferation in hypoxia-induced hPASCs, and promoted cell apoptosis with an increase in the BCL2 associated X/BCL2 ratio and the expression levels of Caspase-3 and Caspase-9. In addition, overexpression of miR-760 suppressed the migration of hPASCs under hypoxic conditions. Furthermore, miR-760 was demonstrated to mediate its anti-proliferation effect via the regulation of toll-like receptor 4 (TLR4), a direct target of miR-760. The results revealed that knockdown of TLR4 restrained the hypoxia-induced hPASC proliferation and induced cell apoptosis. The present study uncovered a novel regulatory pathway involving miR-760 and suggested that miR-760 may be explored as a potential therapy for PAH in the future.

## Introduction

Pulmonary arterial hypertension (PAH), characterized by a progressive increase of lung vascular resistance and

pressure, can gradually lead to death (1,2). The major pathological feature of PAH is structural remodeling of small pulmonary vessels, manifested by excessive human pulmonary artery smooth muscle cell (hPASC) proliferation and migration, apoptotic resistance, accumulation of extracellular matrix and inflammatory responses (3,4). These remodeled vessels contribute to increased pulmonary vascular resistance, which strains and remodels the heart (5). Despite the understanding of these mechanisms, treating strategies for this disease are limited and survival has improved modestly (6).

MicroRNAs (miRNAs) are a kind of endogenous non-coding RNAs found in eukaryotes, with a size of ~20-25 nucleotides, which negatively regulate gene expression by targeting specific messenger RNAs (7). A previous study has confirmed that miRNA-mediated gene expression is important in cardiovascular development (8). The aberrant expression of miRNA has been involved in the pathobiology of PAH (9,10), with important roles in hPASC proliferation, apoptosis and migration (11). It has been reported that miR-4632 inhibits proliferation and promotes apoptosis of hPASCs targeting Jun proto-oncogene (12). Similarly, miR-17 is upregulated in hPASCs treated with hypoxia and lung tissues of PAH patients, and acts as a potential regulator of proliferation and apoptosis in hPASCs (13).

miR-760, a biomarker of colorectal cancer, is significantly downregulated in colorectal cancer and correlated with patient clinicopathological features (14). miR-760 also leads to epithelial-mesenchymal transition in breast cancer cells (15). In the present study, the role of miR-760 in hPASCs was investigated. hPASCs, unlike cardiac and skeletal myocytes, can switch to a highly proliferative and migratory state under various stimuli, such as hypoxia and vascular injury (16,17). It was hypothesized that hypoxia-induced downregulation of miRNAs may target toll-like receptor 4 (TLR4), an innate and adaptive immune cell receptor of the pathogen recognition receptor family linking nonspecific immunity and specific immunity, and may contribute to enhancing hPASC proliferation and migration. The present study reported for the first time that miR-760 levels were reduced under hypoxic conditions, and that miR-760 regulated hypoxia-induced hPASCs proliferation, migration and apoptosis by targeting TLR4. These findings suggested that miR-760 may act as novel therapeutic target for PAH.

*Correspondence to:* Professor Wei Peng, Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing, Jiangsu 210000, P.R. China  
E-mail: pengwei10094@sina.com

\*Contributed equally

**Key words:** pulmonary arterial hypertension, miR-760, toll-like receptor 4, human pulmonary artery smooth muscle cells, hypoxia, proliferation

## Materials and methods

**Acquisition of human lung tissues.** Human lung tissues were acquired from idiopathic PAH patients undergoing lung transplantation and from normal controls. This experiment was approved by the Ethics Committee of Nanjing Medical University (Nanjing, China), and informed consent was obtained from all the participants prior to the study.

**Cell culture and transfection.** hPASMCs were isolated from 16 donors not suitable for lung transplantation with PAH, and isolated as previously described (18).

HPASMCs were cultured in SmBM medium supplemented with 5% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells were grown in 5% CO<sub>2</sub> at 37°C. For induction of hypoxia, cells were cultured in a hypoxia incubator (Thermo Fisher Scientific, Inc.) with 3% O<sub>2</sub>, 5% CO<sub>2</sub>, and balanced nitrogen.

Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) reagent was used to transfect 100 ng of miR-760 mimics (forward, 5'-CGGCUCUGGGUCUGUGGGGA-3', reverse, 5'-UCCCACAGACCCAGAGCCG-3') and 100 ng of negative control (NC) (forward, 5'-ACGUGACACGUUCGGAGA AUU-3', reverse, 5'-UCCCACAGACCCAGAGCCG-3') for 48 h at 37°C, according to the instructions. Small interfering (si)RNA targeting TLR4 (100 ng) (forward, 5'-GGACAGCUU AUAACCUUAATT-3', reverse, 5'-UUAAGGUUAUAAGCU GUCCTT-3') and siRNA control (forward, 5'-UUCUCCGAA CGUGUCACGUTT-3', reverse, 5'-ACGUGACACGUUCG GAGAATT-3') were transfected to hPASMCs to inhibit the expression of TLR4 for 48 h at 37°C.

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Total RNA was isolated from human lung tissues and hPASMCs with the miRNeasy Mini kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's protocol. cDNA was generated from 2 µg pretreated RNA with iScript cDNA Synthesis kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). QRT-PCR was performed using SYBR Premix Ex TaqII (Takara Biotechnology Co., Ltd.) and amplification occurred under the following conditions: Initial 95°C for 10 min, and 40 cycles of 95°C for 15 sec, 55°C for 30 sec, and 70°C for 60 sec. The U6 small nuclear RNA gene was used as the internal control, using the 2<sup>-ΔΔC<sub>q</sub></sup> method (19). Sequences of qPCR primers were designed using the Primer Express Software version 2.0 (Applied Biosystems, Norwalk, CT, USA) as follows: miR-760 forward, 5'-TATTGCTTAAGA ATACGCGTAG-3' and reverse, 5'-AACTCCAGCAGGACC ATGTGAT-3'; TLR4 forward, 5'-AAGTTATTGTGGTGG TGTCTAG-3' and reverse, 5'-GAGGTAGGTGTTTCTGCT AAG-3'; U6 forward, 5'-AGAAGGCTGGGGCTCATTTG-3' and reverse 5'-AGGGGCCATCCACAGTCTTC-3'.

**Immunofluorescence.** hPASMCs were confirmed by immunofluorescence staining for α-actin and succinate receptor 1 (SUCNR1, also known as GPR91). Cells were fixed with 4% formaldehyde for 15 min at room temperature and incubated in 5% Tris buffered saline with Tween-20 diluted non-fat dry milk for 1 h. Immunofluorescence staining was performed using α-actin (ab5694; 1:500; Abcam, Cambridge, UK) and

GPR91 primary antibody (ab140795; 1:500; Abcam) incubation overnight at 4°C, and Alexa Fluor 488 anti-rabbit IgG secondary antibody (ab150077; 1:1,000; Abcam) incubation at room temperature for 1 h. Cells were incubated using DAPI for nuclear staining at room temperature for 30 min. Microscopic analysis was performed with a confocal laser-scanning microscope (Leica Microsystem GmbH, Wetzlar, Germany). For the EdU assay, EdU was added to the culture medium for 8 h. The cultured cells were then fixed with 4% paraformaldehyde for 20 min. Following incubation with 0.2% Triton X-100 to permeabilize the nuclear membrane for 10 min at room temperature, the cells were blocked with PBS containing 10% goat serum (Gibco; Thermo Fisher Scientific, Inc.) for 1 h at 25°C. Then, hPASMCs were stained using the Cell-Light EdU Apollo 488 *In Vitro* Imaging kit (Thermo Fisher Scientific, Inc.). For Ki-67 staining, following fixation, hPASMCs were incubated with Ki-67 antibody (ab156956; 1:1,000; Abcam) at 4°C overnight and then stained with anti-rabbit immunoglobulin G antibody (ab150084; 1:2,000; Abcam) for 2 h at room temperature. Then, cells were incubated using DAPI for staining at room temperature for 30 min. Finally, cells were observed under a fluorescence microscope.

**Cell proliferation assay.** Cell proliferation was assessed by Cell Counting Kit-8 (CCK-8) according to the manufacturer's instructions. The optical density (OD) at 450 nm was recorded on a Microplate Reader (Bio-Rad Laboratories, Inc.).

**Flow cytometry analysis of cells apoptosis.** Apoptosis rates were evaluated by flow cytometry (FACSCalibur; BD Biosciences, San Jose, CA, USA) using an Annexin V-FITC Apoptosis Detection Kit (Abcam) according to the manufacturer's protocol. Briefly, after transfection for 48 h, cells were harvested and 500 µl buffer, 5 µl fluorescein isothiocyanate (FITC)-Annexin V, and 5 µl propidium iodide (PI) were added. The fluorescence of the stained cells was then detected by flow cytometry and analyzed using FlowJo 7.6.1 (FlowJo, LLC).

**Hoechst 33342 staining for apoptosis detection.** After transfection for 48 h, cells were stained with Hoechst33342 (10 mg/ml) at room temperature in the dark for 20 min. Cells were washed with PBS and evaluated using a fluorescence microscope.

**Western blotting.** Proteins extracted from hPASMCs using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Nanjing, China) were subjected to western blotting. Proteins were quantified using a Micro BCA protein assay kit (Pierce; Thermo Fisher Scientific, Inc.). Total cell lysates (30 µg) were loaded in each lane and separated using 12% SDS-PAGE, and transferred to a polyvinylidene fluoride membrane. The membranes were then blocked with 5% skim milk solution at room temperature for 2 h, followed by overnight incubation at 4°C with the appropriate primary antibodies, including anti-Bcl-2 antibody (ab32124; 1:1,000; Abcam), anti-Bax antibody (ab32503; 1:1,000; Abcam), anti-Caspase-3 antibody (ab13585; 1:1,000; Abcam), anti-Caspase-9 antibody (ab32539; 1:1,000; Abcam), GAPDH (ab8245; 1:2,000; Abcam). Then, membranes were incubated with the appropriate horseradish-peroxidase-conjugated IgG

secondary antibodies for (ab97023; 1:5,000; Abcam) 1 h at 25°C. The signals were detected using BeyoECL Moon (Beyotime Institute of Biotechnology) and analyzed using Bio-Rad Laboratories Quantity One software 3.0 (Bio-Rad Laboratories, Inc.).

**Wound-healing assay.** Wound-healing assay was performed to evaluate the migration ability of hPASCs. Briefly, cells ( $6 \times 10^5$  cells/well) were seeded in a 6-well plate and grown to 80–90% confluence. After aspiration of the medium, the center of cell monolayer was scraped with a yellow pipette tip to create a denuded zone of constant width. Wound closure was photographed at 0, 24 and 48 h with a Nikon inverted microscope (Nikon Corporation, Tokyo Japan).

**Transwell migration analysis.** The transwell migration assay was performed using transwell chambers with 10 mm diameter and 8  $\mu$ m pore size polycarbonate membranes (Corning Incorporated, Corning, NY, USA). A total of 200  $\mu$ l cell suspension ( $10^5$  cells) in serum-free medium was added to the upper chambers. The bottom chambers were filled with 500  $\mu$ l medium supplemented with 20% FBS, and the cells were allowed to migrate for 24 h at 37°C. Then, cells in the upper surface of the membrane were removed with a cotton swab. Cells that had crossed to the lower surface of the membrane were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The migrated cells on the lower surface of the membrane filter (an average of five high-power fields per chamber) were counted with a light microscope.

**Luciferase reporter assay.** The wild-type or mutant 3' untranslated region (UTR) of TLR4 was cloned into the pGL3 vector (Promega Corporation, Madison, WI, USA), to confirm direct target association. The wild-type contained binding sites of TLR4 3'UTR with miR-760. Cells ( $2 \times 10^4$ ) in each well were mixed in medium with 10% FBS and incubated for 48 h. miR-760 or negative precursor control were transfected into cells by employing Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc). After 24 h, *Renilla* luciferase reporter and firefly luciferase reporter were transfected into cells in 24-well plates. Luciferase activity was measured using a luciferase reporter assay (Promega Corporation, Madison, WI, USA), whose results were normalized into *Renilla* luciferase activities according to the manufacturer's protocol.

**Colony formation.** Cells were plated in 24-well culture plates at  $1 \times 10^4$  cells/well. After incubation for 12 days at 37°C, cells were fixed with 4% paraformaldehyde, and stained in 10% crystal violet. The number of colonies containing  $\geq 50$  cells was counted under a microscope.

**Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay.** TUNEL assay was performed using an *in situ* cell death detection kit (Roche, Basel, Switzerland), following the manufacturer's instructions. Staining was observed using a light microscope (Nikon Corporation). The ratio of apoptotic cardiomyocytes was presented as % of TUNEL-positive cells to total number of cells.

**Statistical analysis.** All quantitative data were expressed as the mean  $\pm$  standard deviation ( $n=3$ ). GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA) was used to perform all statistical analysis. When only two groups were compared, Student's t-test was conducted. One-way analysis of variance followed by Tukey's post-hoc test was applied to compare differences between multiple groups. For correlation of miR-760 and TLR4 expression, the data was analyzed using Spearman's correlation.  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

**miR-760 is downregulated in PAH lung tissues and hypoxia-induced hPASCs.** Uncontrolled cell proliferation and reduced apoptosis of hPASCs are the predominant factors of pulmonary remodeling (20). To investigate whether the expression of miR-760 is associated with PAH, the expression levels of miR-760 were detected in PAH lung tissues using RT-qPCR analysis. The results demonstrated that the expression levels of miR-760 were significantly lower in PAH lung tissues compared with matched normal lung tissues (Fig. 1A). Furthermore, hPASCs were cultured *in vitro*, in order to analyze the expression levels of miR-760 *in vitro*. The identity of the isolated hPASCs was confirmed by immunofluorescence staining for smooth muscle cell  $\alpha$ -actin and GPR91 (Fig. 1B) (21). Hypoxia is an important stimulus for hPASC proliferation and PAH (22), therefore, the effect of miR-760 in hypoxia-treated and control hPASCs was investigated. RT-qPCR analysis revealed that expression of miR-760 was dramatically downregulated in hypoxia-induced hPASCs compared with the normoxic control (Fig. 1C). These results suggested that downregulation of miR-760 may be involved in the pathogenesis of PAH.

**miR-760 regulates hypoxia-induced hPASC proliferation.** The expression of miR-760 was demonstrated to be downregulated in PAH tissues and hypoxia-induced hPASCs, suggesting that miR-760 may function in regulating the proliferation phenotype of the pulmonary vasculature. To examine the functional role of miR-760, hPASCs were transfected with miR-760 mimics, which resulted in a ~45% increase of miR-760 levels in hypoxia-induced hPASCs (Fig. 2A). To explore the effect of miR-760 on hPASCs proliferation, three different methods were employed: CCK-8, EdU incorporation and Ki-67 staining. The results demonstrated that the total number of hPASCs notably increased when cells were in a hypoxic environment compared with the normoxic control, however, the miR-760 mimics dramatically suppressed the increase of cell numbers in the hypoxia-induced group compared with the blank group and the NC group (Fig. 2B). In accordance with the CCK-8 assay, hypoxia significantly increased the % of EdU positive cells and Ki-67 positive cells compared with the normoxic control, while transfection with the miR-760 mimics reversed this effect (Fig. 2C and D). These results suggested that miR-760 mimics dramatically reduced the hypoxia-induced hPASC proliferation.

**miR-760 regulates hypoxia-induced hPASC apoptosis.** Decreased apoptotic activity has been reported in hPASCs from PAH patients (13). To confirm the role of miR-760 on




Figure 1. miR-760 is downregulated in PAH lung tissues and hypoxia-induced hPASMCs. (A) Expression levels of miR-760 in PAH and normal lung tissues. (B) Immunofluorescence staining analysis for the expression of hPASMC-specific markers (magnification, x400). (C) Expression levels of miR-760 in hypoxia-induced and in control normoxic hPASMCs. \* $P < 0.05$  vs. the control. PAH, pulmonary arterial hypertension; hPASMC, human pulmonary artery smooth muscle cell; GPR91, succinate receptor 1.

hypoxia-induced hPASMC apoptosis, the apoptosis rate was measured by flow cytometry. The results from flow cytometry analysis indicated that the number of apoptotic hPASMCs was remarkably decreased under hypoxic conditions compared with the normoxic control, while miR-760 mimics significantly promoted hypoxia-induced hPASMC apoptosis (Fig. 3A). Furthermore, cell apoptosis was evaluated by morphological examination under fluorescence microscopy following Hoechst 33342 staining. Apoptotic cells exhibit nuclear chromatin condensation and dense staining gathered at the nuclear membrane with pyknosis or fragmentation of apoptotic bodies. The results demonstrated that hPASMCs were uniformly stained by the dye in the normoxic condition, indicating intact cell plasma membrane. However, transfection with the miR-760 mimics significantly promoted hypoxia-induced hPASMCs apoptosis and resulted in an increase of necrotic cells (Fig. 3B). In addition, the TUNEL assay revealed that miR-760 mimics significantly promoted hypoxia-induced hPASMC apoptosis (Fig. 3C). Finally, apoptosis-related proteins, including BCL2 associated X (Bax), BCL2 apoptosis regulator (Bcl-2), Caspase-3 and Caspase-9, were examined by western blot analysis. The results suggested that hypoxia resulted in a decrease in the Bax/Bcl-2 ratio and in the expression levels of Caspase-3 and Caspase-9 in hPASMCs, whereas this effect was ameliorated in the miR-760 mimics group (Fig. 3D).

**miR-760 modulates hypoxia-induced hPASMC migration.** Both PASMC proliferation and migration contribute to pathogenic pulmonary vascular remodeling in PAH (17). In a wound-healing assay, the migration ability of hPASMCs clearly increased when cells were exposed to hypoxia

compared with normoxic conditions (Fig. 4A). However, overexpression of miR-760 mimics resulted in a reduction of cell migration induced by hypoxia (Fig. 4A). In accordance with the wound-healing assay, a transwell experiment revealed similar results; miR-760 mimics suppressed the migration ability of hypoxia-induced hPASMCs (Fig. 4B). This significant reduction in migratory capacity under hypoxic conditions suggests a potential important role of miR-760 during the process of pulmonary vascular remodeling.

**TLR4 is a direct target of miR-760 in hypoxia-induced hPASMCs.** To gain novel insights into the molecular mechanisms underlying the function of miR-760 in modulating hPASMCs, the target of miR-760 was identified. TargetScan, a miRNA prediction software, was employed (23). The results revealed that TLR4 was a binding target of miR-760 (Fig. 5A). Luciferase reporter assays were then performed to confirm that miR-760 regulates directly the expression TLR4. An increase of luciferase activity was observed when cells were co-transfected with miR-760 mimics and mutant TLR4 3'UTR, whereas no change was observed in cells co-transfected with miR-760 and wild-type TLR4 3'UTR (Fig. 5B). To determine whether miR-760 suppressed the expression of TLR4, RT-qPCR and western blot analyses were conducted. As illustrated in Fig. 5C and D, the mRNA and protein levels of TLR4 significantly increased under hypoxic conditions compared with the normoxic control, while overexpression of miR-760 dramatically decreased the mRNA and protein levels of TLR4. Taken together, these results indicated that TLR4 is a direct target of miR-760.






Figure 2. miR-760 regulates hypoxia-induced hPASC proliferation. (A) Expression levels of miR-760 in hypoxia-induced hPASCs following transfection with control or miR-760 mimics. (B) Cell Counting Kit-8 assay was performed to test cell proliferation in hypoxia-induced hPASCs transfected with miR-760 mimics. (C) Ki-67 staining in hypoxia-induced hPASCs transfected with miR-760 mimics (magnification, x200). (D) EdU incorporation assay in hypoxia-induced hPASCs transfected with miR-760 mimics (magnification, x200). Normoxic cells were used as the control group. Untransfected hypoxic cells were the blank group. <sup>#</sup>P<0.05 vs. control; <sup>\*</sup>P<0.05 vs. blank. hPASC, human pulmonary artery smooth muscle cell; NC, negative control.

**Silencing of TLR4 suppresses hypoxia-induced hPASC proliferation and induces apoptosis.** To investigate the effect of TLR4 on cell proliferation, the expression of TLR4 was silenced with siRNA. RT-qPCR and western blot analyses were performed to assess the transfection efficiency, and the results revealed that the mRNA and protein levels of TLR4 significantly decreased in the siRNA TLR4 group compared with the siRNA NC group (Fig. 6A and B). In addition, the expression of TLR4 in the hypoxia-induced group clearly increased, while silencing of TLR4 significantly ameliorated the effect (Fig. 6C). Furthermore, silencing of TLR4 dramatically suppressed cell colony formation and promoted apoptosis in hPASCs under hypoxic conditions (Fig. 6D and E). Finally, the transwell assay and wound-healing assay

results indicated that silencing of TLR4 could ameliorate the hypoxia-induced increase of cell migration (Fig. 6F and G).

The above results suggested that TLR4 is a direct target of miR-760, and that TLR4 inhibition could decrease cell proliferation and migration, as well as induce cell apoptosis in hypoxia-induced hPASCs. Next, RT-qPCR and western blot experiment were performed to explore the expression of TLR4 in PAH lung tissues. The data confirmed that mRNA and protein levels of TLR4 were upregulated in PAH lung tissues compared with normal lung tissues (Fig. 6H and I). Furthermore, the relationship between the expression of TLR4 and miR-760 was investigated in PAH lung tissues, and the result indicated that the expression of TLR4 was inversely correlated with the levels of miR-760 (Fig. 6J).




Figure 3. miR-760 regulates hypoxia-induced hPASC apoptosis. (A) Flow cytometry was performed to examine apoptosis in hypoxia-induced hPASCs. (B) Hoechst 33342 staining was used to examine morphological changes related to apoptosis (magnification, x400). (C) Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay was performed to evaluate hypoxia-induced hPASC apoptosis (magnification, x200). (D) Western blotting was performed to examine the expression levels of apoptosis-related proteins. \* $P < 0.05$  vs. control; # $P < 0.05$  vs. blank. hPASC, human pulmonary artery smooth muscle cell; NC, negative control; PI, propidium iodide; FITC, fluorescein isothiocyanate; Bax, BCL2 associated X; Bcl-2, BCL2 apoptosis regulator.

## Discussion

PAH is a chronic progressive and fatal disease (24), which is characterized by a continuous increase in pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart failure and death (25). The pathogenesis of PAH is associated with inflammation, increased vascular tension and hPASC proliferation, as well as resistance to apoptosis (4). The current available therapy options to improve long-term prognosis of PAH are limited (26). The present study provided evidence of the role of miR-760 and its posttranscriptional regulation of TLR4 in the pathogenesis of PAH and highlighted its potential as a novel therapeutic target for PAH.

As a well-known cause of PAH in patients, hypoxia has been widely used to generate animal or cell models of PAH (27). Hypoxia-induced inflammation, excessive proliferation and inhibition of apoptosis in hPASCs are involved

in the pathological process of hypoxic PAH (28). Previous research has reported that exposure of rats to hypoxia resulted in disruption of endothelial membrane integrity and hPASC proliferation (29). The present study demonstrated that hPASC proliferation, as measured by CCK-8, EdU and Ki-67 assays, was dramatically increased when cells were in a hypoxic environment, while transfection with miR-760 mimics clearly ameliorated this effect. In multicellular animals, the morphology and function of organs are precisely regulated by cell proliferation, division and apoptosis, which are activated by extracellular factors (30). Apoptosis is an important physiological process, which can cause the decrease of PASCs and pressure of pulmonary artery (31). The increase of proliferation and the decrease of apoptosis in PASCs can enhance the thickness of the pulmonary arteriole wall, narrow the pulmonary artery lumen, and increase the pulmonary vascular resistance and the pulmonary arterial pressure (32). In the present study, the results indicated that the number of




Figure 4. miR-760 modulates hypoxia-induced hPASC migration. Cell migration was assayed in hypoxia-induced hPASCs following transfection with miR-760 mimics, by (A) wound-healing assay (magnification, x100), and by (B) transwell assay (magnification, x200). \* $P < 0.05$  vs. control; \* $P < 0.05$  vs. blank. hPASC, human pulmonary artery smooth muscle cell; NC, negative control.




Figure 5. TLR4 is a direct target of miR-760 in hypoxia-induced hPASCs. (A) Binding between miR-760 and the TLR4 3' UTR was predicted by TargetScan software analysis. (B) Luciferase reporter assays were performed to confirm the binding of miR-760 in the 3' UTR of TLR4. (C) Western blot analysis and (D) reverse transcription-quantitative polymerase chain reaction assay were performed to detect the protein and mRNA levels of TLR4 in hPASCs. \* $P < 0.05$  vs. control; \* $P < 0.05$  vs. blank. TLR4, toll-like receptor 4; hPASC, human pulmonary artery smooth muscle cell; UTR, untranslated region; WT, wild-type; MUT, mutant; NC, negative control.

apoptotic hPASCs was remarkably decreased under hypoxic conditions, while miR-760 mimics significantly promoted hypoxia-induced hPASC apoptosis. Bcl-2 gene family proteins are important regulatory factors of cell apoptosis, and they have crucial roles in the apoptosis pathway, including Bcl-2 and Bax. Bcl-2 is an inhibitor of apoptosis, while Bax promotes apoptosis (33). The current results suggested that miR-760 mimics significantly increased the Bax/Bcl-2 protein ratio in hPASCs induced by hypoxia. Migration of

hPASCs contributes to vascular remodeling in pulmonary hypertension (34). The current data demonstrated that migration of hypoxia-induced hPASCs was remarkably decreased in the miR-760 mimics group.

Toll-like receptors are an important class of proteins involved in nonspecific immunity, which also link nonspecific immunity and specific immunity. TLR4, a germline-encoded pattern recognition receptor, serves a vital function in inflammatory responses (35). It has been reported that hypoxia






Figure 6. TLR4 silencing suppresses hypoxia-induced cell proliferation and induces apoptosis. (A) Silencing of TLR4 by siRNA was confirmed at the mRNA and the (B) protein level. (C) mRNA expression levels of TLR4 in hypoxia-induced hPASMCs following TLR4 siRNA transfection. (D) Colony formation assay in hypoxia-induced hPASMCs (magnification, x200). (E) Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay was performed to examine cell apoptosis in hypoxia-induced hPASMCs (magnification, x200). (F) Transwell assays (magnification, x200) and (G) wound-healing assays (magnification, x100) were performed to examine the migration ability of hypoxia-induced hPASMCs. (H) Western blot and (I) reverse transcription-quantitative polymerase chain reaction analyses were used to detect the mRNA and protein expression levels, respectively, of TLR4 in PAH and normal lung tissues. (J) Correlation analysis of miR-760 and TLR4 expression in PAH lung tissues. \* $P < 0.05$  vs. control; # $P < 0.05$  vs. blank. TLR4, toll-like receptor 4; si, small interfering; hPASMC, human pulmonary artery smooth muscle cell; PAH, pulmonary arterial hypertension; NC, negative control.

decreases TLR4 expression and induces reactive oxygen species and Nox1/Nox4 in PASMCs (36). In the present study, the results demonstrated that TLR4 was a direct target of miR-760 in hypoxia-induced hPASMCs, and silencing of TLR4 by siRNA could restrain hypoxia-induced cell proliferation and induce apoptosis. In addition, the expression of TLR4 was inversely correlated with the levels of miR-760 in PAH lung tissues.

In conclusion, the present study revealed that miR-760 may have an essential role in PAH, via regulation of TLR4.

Upregulation of miR-760 drastically inhibited hPASMC proliferation and migration, as well as induced hPASMC apoptosis under hypoxic conditions, by targeting TLR4. Further studies focusing on the functional interaction between miR-760 and TLR4 might contribute to the development of novel therapeutic targets for PAH.

#### Acknowledgements

Not applicable.



## Funding

The present study was supported by Nanjing Medical Science and Technique Development Foundation (grant nos. 201405013 and YKK15136).

## Availability of data and material

The analyzed datasets generated during the study are available from the corresponding author on reasonable request.

## Authors' contributions

YZY, YFZ and WP conceived and designed the experiments. LY and JX performed the experiments. XMM analyzed the data. YZY and WP wrote the paper. All authors read and approved the final manuscript.

## Ethics approval and consent to participate

The experimental protocols were approved by the Ethics Committee of Nanjing Medical University, and informed consent was obtained from all the participants prior to the study.

## Patient consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## References

- Sahoo S, Meijles DN, Ghoulah IA, Tandon M, Cifuentes-Pagano E, Sembrat J, Rojas M, Goncharova E and Pagano PJ: MEF2C-MYOC and Leiomodin1 suppression by miRNA-214 promotes smooth muscle cell phenotype switching in pulmonary arterial hypertension. *PLoS One* 11: e0153780, 2016.
- Farber HW and Loscalzo J: Mechanisms of disease: Pulmonary arterial hypertension. *N Engl J Med* 351: 1655-1665, 2004.
- Tuder RM, Marecki JC, Richter A, Fijalkowska I and Flores S: Pathology of pulmonary hypertension. *Clin Chest Med* 28: 23-42, 2007.
- Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, *et al*: Cellular and molecular basis of pulmonary arterial hypertension. *J Am Coll Cardiol* 54: S20-S31, 2009.
- Hadri L, Kratljan RG, Benard L, Maron BA, Dorfmueller P, Ladage D, Guignabert C, Ishikawa K, Agüero J, Ibanez B, *et al*: Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. *Circulation* 128: 512-523, 2013.
- Rubin LJ, Simonneau G, Badesch D, Galie N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O and Kymes S: The study of risk in pulmonary arterial hypertension. *Eur Respir Rev* 21: 234-238, 2012.
- Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB and Bartel DP: The widespread impact of mammalian microRNAs on mRNA repression and evolution. *Science* 310: 1817-1821, 2005.
- Arunachalam G, Upadhyay R, Ding H and Triggle CR: MicroRNA signature and cardiovascular dysfunction. *J Cardiovasc Pharmacol* 65: 419-29, 2015.
- Bienertova-Vasku J, Novak J and Vasku A: MicroRNAs in pulmonary arterial hypertension: Pathogenesis, diagnosis and treatment. *J Am Soc Hypertens* 9: 221-34, 2015.
- Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, Breuils-Bonnet S, Mai D, Navab K, Ross D, *et al*: ApoA-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. *Circulation* 130: 776-785, 2014.
- Courboulain A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, *et al*: Role for miR-204 in human pulmonary arterial hypertension. *J Exp Med* 208: 535-548, 2011.
- Qian Z, Li Y, Chen J, Li X and Gou D: miR-4632 mediates PDGF-BB-induced proliferation and antiapoptosis of human pulmonary artery smooth muscle cells via targeting cJUN. *Am J Physiol Cell Physiol* 313: C380-C391, 2017.
- Lu Z, Li S, Zhao S and Fa X: Upregulated miR-17 regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation and apoptosis by targeting mitofusin 2. *Med Sci Monit* 22: 3301-3308, 2016.
- Elshafei A, Shaker O, Abd-El-Motaal O and Salman T: The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study. *Tumor Biol* 39: 1010428317705765, 2017.
- Hu SH, Wang CH, Huang ZJ, Liu F, Xu CW, Li XL and Chen GQ: miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells. *Eur Rev Med Pharmacol Sci* 20: 5002-5008, 2016.
- Hao H, Gabbiani G and Bochaton-Piallat ML: Arterial smooth muscle cell heterogeneity: Implications for atherosclerosis and restenosis development. *Arterioscler Thromb Vasc Biol* 23: 1510-1520, 2003.
- Sysol JR, Chen J, Singla S, Zhao S, Comhair S, Natarajan V and Machado RF: MicroRNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1. *Am J Physiol Lung Cell Mol Physiol* 314: L461-L472, 2018.
- Aytekin M, Comhair SA, de la Motte C, Bandyopadhyay SK, Farver CF, Hascall VC, Erzurum SC and Dweik RA: High levels of hyaluronan in idiopathic pulmonary arterial hypertension. *Am J Physiol Lung Cell Mol Physiol* 295: L789-L799, 2008.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-ΔΔC<sub>T</sub></sup> method. *Method* 25: 402-408, 2001.
- Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF and Ishizaki T: p53 gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. *Am J Physiol Lung Cell Mol Physiol* 300: L753-L761, 2011.
- Ma J, Liang S, Wang Z, Zhang L, Jiang J, Zheng J, Yu L, Zheng X, Wang R and Zhu D: ROCK pathway participates in the processes that 15-hydroxyeicosatetraenoic acid (15-HETE) mediated the pulmonary vascular remodeling induced by hypoxia in rat. *J Cell Physiol* 222: 82-94, 2010.
- Jafali S, Ramanathan GK, Parthasarathy PT, Aljbran S, Galam L, Yunus A, Garcia S, Cox RR Jr, Lockey RF and Kolliputi N: Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. *PLoS One* 7: e46808, 2012.
- Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNA. *Elife* 4, 2015.
- de Jesus Perez V, Yuan K, Alastalo TP, Spiekerkoetter E and Rabinovitch M: Targeting the Wnt signaling pathways in pulmonary arterial hypertension. *Drug Discov Today* 19: 1270-1276, 2014.
- Anwar A, Li M, Frid MG, Kumar B, Gerasimovskaya EV, Riddle SR, McKeon BA, Thukaram R, Meyrick BO, Fini MA and Stenmark KR: Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* 303: L1-L11, 2012.
- McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, *et al*: ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol* 53: 1573-1619, 2009.
- Liu A, Philip J, Vinnakota KC, Van den Bergh F, Tabima DM, Hacker T, Beard DA and Chesler NC: Estrogen maintains mitochondrial content and function in the right ventricle of rats with pulmonary hypertension. *Physiol Rep* 5: e13157, 2017.

28. Jin H, Wang Y, Zhou L, Liu L, Zhang P, Deng W and Yuan Y: Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells. *J Pineal Res* 57: 442-450, 2014.
29. Welsh DJ and Peacock AJ: Cellular responses to hypoxia in the pulmonary circulation. *High Alt Med Biol* 14: 111-116, 2013.
30. Cui C, Zhang H, Guo LN, Zhang X, Meng L, Pan X and Wei Y: Inhibitory effect of NBL1 on PDGF-BB-induced human PASMC proliferation through blockade of PDGF $\beta$ -p38MAPK pathway. *Biosci Rep* 36: e00374, 2016.
31. Stenmark KR, Meyrick B, Galie N, Mooi WJ and McMurtry IF: Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. *Am J Physiol Lung Cell Mol Physiol* 297: L1013-L1032, 2009.
32. Yuan JX and Rubin LJ: Pathogenesis of pulmonary arterial hypertension: The need for multiple hits, *Circulation* 111: 534-538, 2005.
33. Karbowski M, Norris KL, Cleland MM, Jeong SY and Youle RJ: Role of Bax and Bak in mitochondrial morphogenesis. *Nature* 443: 658-662, 2006.
34. Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA and Krymskaya VP: PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol* 283: L354-L363, 2002.
35. Wang YC, Lin S and Yang QW: Toll-like receptors in cerebral ischemic inflammatory injury. *J Neuroinflammation* 8: 134, 2011.
36. Ma L, Ambalavanan N, Liu H, Sun Y, Jhala N, Bradley WE, Dell'Italia LJ, Michalek S, Wu H, Steele C, Benza RL and Chen Y *et al*: TLR4 regulates pulmonary vascular homeostasis and remodeling via redox signaling. *Front Biosci* 21: 397-409, 2016.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

RETRACTED